• Home
  • Radiologists
  • Divisions
    • Abdominal
    • Breast
    • Cardiothoracic
    • Interventional Radiology
    • Molecular Imaging
    • Musculoskeletal
    • Neuroradiology
  • Activities
    • AI
    • AIEC
    • Business
    • Diversity/Equity/Inclusion
    • Education
    • Faculty Development
    • Innovation
    • IT
    • Primary Care rep.
    • Quality & Safety
    • Research
  • Research
  • Hospitals
    • Toronto General Hospital
    • Toronto Western Hospital
    • Princess Margaret Cancer Centre
    • Women’s College Hospital
    • Sinai Health
  • About JDMI
Radiologists - (UHN, WCH, Sinai Health), UofT Radiologists - (UHN, WCH, Sinai Health), UofT Radiologists - (UHN, WCH, Sinai Health), UofT Radiologists - (UHN, WCH, Sinai Health), UofT Radiologists - (UHN, WCH, Sinai Health), UofT
  • Home
  • Radiologists
  • Divisions
    • Abdominal
    • Breast
    • Cardiothoracic
    • Interventional Radiology
    • Molecular Imaging
    • Musculoskeletal
    • Neuroradiology
  • Activities
    • AI
    • AIEC
    • Business
    • Diversity/Equity/Inclusion
    • Education
    • Faculty Development
    • Innovation
    • IT
    • Primary Care rep.
    • Quality & Safety
    • Research
  • Research
  • Hospitals
    • Toronto General Hospital
    • Toronto Western Hospital
    • Princess Margaret Cancer Centre
    • Women’s College Hospital
    • Sinai Health
  • About JDMI
Ur Metser

Ur Metser, MD, FRCPC

    • Site Director, Princess Margaret Cancer Centre
    • Division Head, Molecular Imaging

Dr. Ur Metser is the Division Head of Molecular Imaging at the Joint Department of Medical Imaging (UHN, Sinai Health and Women’s College Hospital), Site Director of Medical Imaging at the Princess Margaret Cancer Centre and holds the position of Professor of Radiology, Department of Medical Imaging at the University of Toronto. He is also the clinical lead in the core of Radiochemistry and Nanotechnology at the Techna Institute and chairs the Ontario Provincial Positron Emission Tomography Steering Committee at Cancer Care Ontario, responsible for the evidence-based introduction of PET in Ontario. He graduated from the Faculty of Medicine at the Technion (Haifa) and completed his residency training at the Sourasky Medical Center (affiliate of Tel Aviv University) and fellowship programs in abdominal imaging at the University of Toronto, and PET imaging at McMaster University.

After serving as staff radiologist at the Departments of Radiology and Nuclear Medicine in Tel-Aviv, he joined the Joint Department of Medical Imaging in the Divisions of Abdominal Imaging and Molecular Imaging. He is a fellow of the Royal College of Physicians (Canada) and an active member in multiple international professional societies including the Radiological Society of North America, American Roentgen Ray Society, and Society of Nuclear Medicine, amongst others. Dr. Metser has published over 100 manuscripts in peer-reviewed journals, as well as multiple review articles, book chapters and practice guidelines. He is also a reviewer for a few of the field’s leading medical journals and is on the editorial board of Journal of Computed Axial Tomography.

His main clinical and research interests focus on novel molecular imaging probes, theranostics, hybrid imaging (PET/CT and PET/MR) for tumour detection, characterization and assessment of response to therapy with functional imaging.

View the Molecular Division

Recent Publications

  • Nasopharyngeal Carcinoma Radiomic Evaluation with Serial PET/CT: Exploring Features Predictive of Survival in Patients with Long-Term Follow-Up

    CONCLUSIONS: This study with long-term follow up data on NPC suggests that mainly PET-derived radiomic features are predictive for OS but not PFS in […]

  • Diagnostic performance of [18F]-FDG PET/MR in evaluating colorectal cancer: a systematic review and meta-analysis

    CONCLUSION: This meta-analysis showed an overall high diagnostic performance for [^(18)F]-FDG PET/MR in detecting CRC lesions/metastases. Thus, this […]

  • Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer

    Background Data regarding 2-(3-{1-carboxy-5-[(6-[^(18)F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (^(18)F-DCFPyL) PET in […]

  • Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis

    Background There is limited consensus regarding the relative diagnostic performance of cardiac MRI and fluorodeoxyglucose (FDG) PET for cardiac […]

  • Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer

    CONCLUSIONS: PET and CT radiomics derived from combined PET/CT integrated with clinicopathological parameters and sarcopenia measurement might […]

  • The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

    CONCLUSION: In conclusion, PSMA PET is positive in more than 2/3 of men with BCR and impacts patient management in more than half of the men. BRFS […]

  • Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

    Pretransplant Deauville score (DS) is an imaging biomarker used for risk stratification in relapsed/refractory classical Hodgkin lymphoma (cHL). […]

  • Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation

    CONCLUSION: Detectable plasma HPV DNA at end of CRT predates the clinical diagnosis of metastases and is associated with inferior progression-free […]

  • Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

    Background The high positivity rate of prostate-specific membrane antigen (PSMA) PET in the setting of biochemical failure (BCF), even when […]

  • The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients

    CONCLUSIONS: Thresholds of SUVmax and SUVratio identified a significant proportion of patients who did not develop adrenal metastasis. In oncology […]

  • Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis

    CONCLUSIONS: Combined cardiac FDG-PET/MRI with T1/T2 mapping provides complementary diagnostic information and predicts MACE in patients with […]

  • The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

    CONCLUSION: In patients with SSTR-RADS 5 PM-NETs treated with 177Lu-DOTATATE, there was similar response to therapy for all lesions with […]

  • 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement

    CONCLUSION: This study showed a substantial interobserver agreement in the overall interpretation and detecting locoregional and distant involvement […]

  • Placenta increta mimicking placental site trophoblastic tumor

    No abstract

  • Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

    CONCLUSIONS: Our developed radiomics signature demonstrated modest discriminative accuracy; however, these results may have been influenced by small […]

  • Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease

    CONCLUSIONS: In our series of salvage dissection for PSMA-PET-detected nodal oligometastases, approximately a third achieved PSA

  • Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma

    CONCLUSIONS: The set of radiomic signatures was found to have limited ability to discriminate nivolumab responders from non-responders. The use of […]

  • Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer

    CONCLUSION: Combining the patients' imaging-derived sarcopenic status with standard clinical data, but not metabolic parameters, offered an overall […]

  • 18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center

    CONCLUSION: ^(18)F-DCFPyL PET was positive in >90% of patients with biochemical failure. For those with limited recurrence, PSMA PET-directed […]

  • Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada

    Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming established as a standard of care for […]

  • Management of Wolffian adnexal tumors

    No abstract

  • Neuroendocrine Tumors: Imaging Perspective

    This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics […]

  • Deep learning for whole-body medical image generation

    CONCLUSION: The findings reported here demonstrate the feasibility of this technique and its potential to improve certain aspects of attenuation […]

  • Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

    CONCLUSION: PSMA PET detects more csPCa than mpMR, but at low specificity. The performance PET/MR is better than mpMR for detection of csPCa in […]

  • Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis

    CONCLUSIONS: PSMA-defined oligorecurrent-PCa can be rendered bNED, a necessary step towards cure, in 1 of 5 patients receiving MDT alone. Randomized […]

  • Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

    Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) is increasingly being used worldwide as part of the clinical […]

  • Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis

    CONCLUSION: END is a cost-effective strategy compared with PET-CT in patients who have node-negative oral cancer. Although lower PET standardized […]

  • Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE

    The aim of this study was to determine whether quantitative PET parameters on baseline ^(68)Ga-DOTATATE PET/CT and interim PET (iPET) performed […]

  • Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging

    CONCLUSIONS: Most patients had a major change in actual management compared with pre-PSMA-targeted PET/CT planned management, and this was […]

  • How to Design AI-Driven Clinical Trials in Nuclear Medicine

    Artificial intelligence (AI) is an overarching term for a multitude of technologies which are currently being discussed and introduced in several […]

JDMI Radiologists (University Health Network, Women's College Hospital, Sinai Health), University of Toronto | created by Techna Institute, UHN - 2021